Inactive Instrument

RHINOMED

Equities

RNO

AU000000RNO1

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Rhinomed Completes Minimum Holding Share Buyback Program MT
Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director CI
Rhinomed Completes Strategic Review of Operations MT
Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023 CI
Rhinomed Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Rhinomed Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Rhinomed Limited Announces Supply Agreement with BTNX CI
Rhinomed Secures AU$3.7 Million Capital Facility MT
Rhinomed Limited Auditor Raises 'Going Concern' Doubt CI
Rhinomed Validates Accuracy of Pediatric Nasal Swab MT
Rhinomed Limited Announces Rhinoswab Junior Study Confirms New Nasal Swab Is Most Accurate, Comfortable and Easy for Kids CI
Rhinomed Limited Announces Board Changes CI
Rhinomed Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Rhinomed Limited Receives First Purchase Order for 250,000 Rhinoswab Juniors CI
Rhinomed Grows Fiscal Q4, FY22 Revenue MT
Rhinomed Secures Swab Supply Deal for COVID-19 Rapid Antigen Tests MT
Rhinomed Limited Announces 24 Month Rhinoswab and Rhinoswab Junior Supply Agreement with SureScreen Australia CI
Rhinomed Trading Halt Lifts After Completion of $2.5 Million Institutional Entitlement Offer MT
Rhinomed Enters Two-Year Swab Supply Deal With Canadian Test Kit Manufacturer MT
Rhinomed Limited Enters into Supply Agreement with BTNX Inc CI
Rhinomed Limited Reports Earnings Results for the Half Year Ended December 31, 2021 CI
Rhinomed Receives Nearly $304,000 R&D Tax Rebate; Shares Up 4% MT
Rhinomed Fiscal Q2 Revenue Rises 17% Q-o-Q MT
Rhinomed's Pediatric Nasal Swab Product Meets Primary Endpoint in Device Trial MT
Rhinomed Limited Announces the Interim Results in the World First "Rhinoswab for Diagnosis of Respiratory Virus in Children" Trial CI
Chart RHINOMED
More charts
Rhinomed Limited is an Australia-based wearable nasal technology company. The Company is engaged in the research, development and commercialization of consumer and medical devices. The Company's products include Mute, Turbine, Pronto Sleep, Pronto Clear and Rhinoswab. Mute dilates the nasal passages making nasal breathing easier, reducing mouth breathing and helping to breathe more, snore less and sleep better. Turbine is designed to fit comfortably inside the nose and gently open each individual nostril to allow more airflow during sport, physical exertion or focused breathing, such as yoga and meditation. Rhinoswab is a patented comfortable, self-administered nasal swab that provides high-yield sampling and fits existing pathology workflows. Pronto Sleep is a vapor inhaler that gently opens the nose and delivers a soothing blend of four pure essential oils. Its nasal platform envisages multiple applications from simple stenting through to nasal drug delivery and sensor/diagnostics.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock RHINOMED - Australian S.E.
  4. News RHINOMED
  5. Rhinomed : Registers Nasal Swab With US FDA